Q-omics provides the consensus-scored PRSS1 profile across patient tissues and cancer cell-line models. PRSS1 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, PRSS1 is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, PRSS1 RNA expression shows 13,626 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight UCEC, THCA, and PDAC as cancer lineages where PRSS1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRSS1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRSS1 survival associations across molecular data types. PRSS1 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (6) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRSS1 RNA expression–survival associations across cancer types. High PRSS1 expression shows unfavorable associations in UCEC, STAD and KIRP, but favorable associations in READ, ACC and THCA. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for PRSS1 RNA expression.
This table summarizes PRSS1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 4. The strongest signals are observed in THCA for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for PRSS1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRSS1 shows higher tumor expression in THCA, COAD, LUAD, KICH, UCEC and LUSC. The THCA box plot shows higher PRSS1 RNA expression in tumor versus normal tissue (log2 FC = +1.564, t-test p < 0.001).
This table shows molecular features associated with PRSS1 in patient tissues and cancer cell lines. In patient samples, PRSS1 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, PRSS1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BONE and PANCREAS.
